Sign in

Sneha Muthe

Vice President and Equity Research Analyst at Barclays

Sneha Muthe is a Vice President and Equity Research Analyst at Barclays, specializing in coverage of the India consumer and retail sectors with in-depth focus on companies such as Hindustan Unilever, Dabur, Tata Consumer Products, and Godrej Consumer. Known for her detailed fundamental analysis and actionable investment insights, she has contributed to well-received stock calls, achieving strong performance rankings and being recognized for precise earnings forecasts in her sector. Starting her career at Barclays in 2015 after graduating from the Indian Institute of Management (IIM) Calcutta, Sneha has established herself as a rising expert in consumer equities, having previously interned in research roles at Kotak Mahindra and Accenture. She holds a Chartered Accountant qualification, is a CFA Level III candidate, and maintains necessary SEBI and compliance registrations for equity research in India.

Sneha Muthe's questions to Humacyte (HUMA) leadership

Question · Q3 2025

Sneha Muthe asked about the reorder rate for Symvess among hospitals that have started ordering, following up on previous quarter's VAC process and ordering numbers. She also inquired about the impact of the new V007 trial data on the potential for Symvess in dialysis.

Answer

President and CEO Laura Niklason stated that the majority of hospitals that have started ordering Symvess have also begun the reorder process, though specific data had not been previously disclosed. Regarding the V007 data, Dr. Niklason emphasized the very strong results in duration of usability for high-need subgroups (women and men with diabetes and obesity) over two years, noting this population represents more than half of the dialysis market and will strongly support the supplemental BLA application.

Ask follow-up questions

Fintool

Fintool can predict Humacyte logo HUMA's earnings beat/miss a week before the call

Question · Q3 2025

Sneha Muthe asked about the reorder rates for Symvess among hospitals that have started ordering and how the new V007 trial data impacts the potential for Symvess in dialysis.

Answer

CEO Laura Niklason indicated that the majority of hospitals that have placed initial orders for Symvess have subsequently reordered. Regarding the V007 data, Dr. Niklason emphasized the strong two-year duration of usability results in high-need subgroups (women, diabetics, obese) as crucial support for the upcoming supplemental BLA filing, noting these subgroups represent over half of the dialysis patient population.

Ask follow-up questions

Fintool

Fintool can write a report on Humacyte logo HUMA's next earnings in your company's style and formatting